Show simple item record

dc.contributor.authorToor, Salman M
dc.contributor.authorSyed Khaja, Azharuddin Sajid
dc.contributor.authorEl Salhat, Haytham
dc.contributor.authorBekdache, Omar
dc.contributor.authorKanbar, Jihad
dc.contributor.authorJaloudi, Mohammed
dc.contributor.authorElkord, Eyad
dc.date.accessioned2017-02-07T09:51:44Z
dc.date.available2017-02-07T09:51:44Z
dc.date.issued2016
dc.identifier.citationIncreased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients. 2016, 7:560 Front Immunolen
dc.identifier.pmid28008330
dc.identifier.doi10.3389/fimmu.2016.00560
dc.identifier.urihttp://hdl.handle.net/10541/620141
dc.description.abstractIncreased levels of myeloid cells, especially myeloid-derived suppressor cells (MDSCs), have been reported to correlate with bad prognosis and reduced survival in cancer patients. However, limited data are available on their conclusive phenotypes and their correlation with clinical settings. The aim of this study was to investigate levels and phenotype of myeloid cells in peripheral blood and tumor microenvironment (TME) of colorectal cancer (CRC) patients, compared to blood from healthy donors (HDs) and paired, adjacent non-tumor colon tissue. Flow cytometric analysis was performed to examine the expression of different myeloid markers in fresh peripheral blood samples from CRC patients and HDs, and tissue-infiltrating immune cells from CRC patients. We found significantly higher levels of cells expressing myeloid markers and lacking the expression of major histocompatibility complex class II molecule HLA-DR in blood and tumor of CRC patients. Further analysis revealed that these cells were granulocytic and expressed Arginase 1 indicative of their suppressive phenotype. These expanded cells could be neutrophils or granulocytic MDSCs, and we refer to them as granulocytic myeloid cells (GMCs) due to the phenotypical and functional overlap between these cell subsets. Interestingly, the expansion of peripheral GMCs correlated with higher stage and histological grade of cancer, thereby suggesting their role in cancer progression. Furthermore, an increase in CD33(+)CD11b(+)HLA-DR(-)CD14(-)CD15(-) immature myeloid cells was also observed in CRC tumor tissue. Our work shows that GMCs are expanded in circulation and TME of CRC patients, which provides further insights for developing immunotherapeutic approaches targeting these cell subsets to enhance antitumor immune and clinical responses.
dc.language.isoenen
dc.rightsArchived with thanks to Frontiers in immunologyen
dc.titleIncreased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients.en
dc.typeArticleen
dc.identifier.journalFrontiers in Immunologyen
refterms.dateFOA2018-12-17T14:47:38Z
html.description.abstractIncreased levels of myeloid cells, especially myeloid-derived suppressor cells (MDSCs), have been reported to correlate with bad prognosis and reduced survival in cancer patients. However, limited data are available on their conclusive phenotypes and their correlation with clinical settings. The aim of this study was to investigate levels and phenotype of myeloid cells in peripheral blood and tumor microenvironment (TME) of colorectal cancer (CRC) patients, compared to blood from healthy donors (HDs) and paired, adjacent non-tumor colon tissue. Flow cytometric analysis was performed to examine the expression of different myeloid markers in fresh peripheral blood samples from CRC patients and HDs, and tissue-infiltrating immune cells from CRC patients. We found significantly higher levels of cells expressing myeloid markers and lacking the expression of major histocompatibility complex class II molecule HLA-DR in blood and tumor of CRC patients. Further analysis revealed that these cells were granulocytic and expressed Arginase 1 indicative of their suppressive phenotype. These expanded cells could be neutrophils or granulocytic MDSCs, and we refer to them as granulocytic myeloid cells (GMCs) due to the phenotypical and functional overlap between these cell subsets. Interestingly, the expansion of peripheral GMCs correlated with higher stage and histological grade of cancer, thereby suggesting their role in cancer progression. Furthermore, an increase in CD33(+)CD11b(+)HLA-DR(-)CD14(-)CD15(-) immature myeloid cells was also observed in CRC tumor tissue. Our work shows that GMCs are expanded in circulation and TME of CRC patients, which provides further insights for developing immunotherapeutic approaches targeting these cell subsets to enhance antitumor immune and clinical responses.


Files in this item

Thumbnail
Name:
fimmu-07-00560.pdf
Size:
2.510Mb
Format:
PDF
Description:
Open access full text article

This item appears in the following Collection(s)

Show simple item record